MICO PLUNG

“MycoBiotics” as a new technology platform for the treatment of human respiratory and genital tract diseases

Coordinatore	FUNDACIO CENTRE DE REGULACIO GENOMICA    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	Spain [ES]
Totale costo	165˙429 €
EC contributo	150˙000 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2012-PoC
Funding Scheme	CSA-SA(POC)
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-07-01   -   2014-12-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	FUNDACIO CENTRE DE REGULACIO GENOMICA  Organization address address: CARRER DOCTOR AIGUADER 88 city: BARCELONA postcode: 8003 contact info Titolo: Mr. Nome: Stefan Cognome: Pönisch Email: send email Telefono: +34 93 3160264 Fax: +34 93 3160099	ES (BARCELONA)	hostInstitution	150˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The use of Mycoplasma pneumoniae or its closest relative M. genitalium engineered for the controlled delivery of therapeutic peptides or proteins in situ, i.e. where they currently reside, could open new possibilities for the treatment of lung and genital tract diseases. Taking advantage of the parasite nature of M. pneumoniae to lung tissue, we plan to use genetically engineered forms of this bacterium for the local, and eventually conditional delivery of therapeutic proteins in the context of distinct and many times highly invalidating respiratory disorders, as a proof-of-concept of a new technology platform. Results of the work done at the CRG on the two projects above shall be validated in vitro and in vivo and, if successful, constitute the basis for a licensing agreement, or eventually a spin-off company created to bring the engineered bacteria or modifications thereof into the clinic. Interestingly, additional applications could be proposed at some point to diseases of the genital tract using engineered M. genitalium as a living vector.'